Therefore, a combinatorial therapy of nab-paclitaxel with an aldose-reductase inhibitor might delay the acquisition of nab-paclitaxel resistance in pancreatic cancer [57]. This evidence concerns the gene AKR1B1 and pancreatic neoplasm.